Valerie Brand
Family · New Orleans, LANPI 1609464676
Payments from drug & device makers
Across 50 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$264
- Mayne Pharma Commercial LLC$108
- AstraZeneca$78
- Novo Nordisk$72
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$65
- Idorsia Pharmaceuticals US Inc$58
- plus $411 from 15 others
What the payments were for
- Food & beverage$1,055100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $264 |
| Mayne Pharma Commercial LLC | 5 | $108 |
| AstraZeneca | 4 | $78 |
| Novo Nordisk | 4 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Amgen(2 entities) | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Mylan Specialty L.p. | 3 | $41 |
| Bayer | 2 | $38 |
| Pfizer | 2 | $36 |
| Gilead | 1 | $26 |
| Johnson & Johnson | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Exact Sciences | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,055 in reported general payments places this provider in the 60th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 26 | $334 |
| Atorvastatin Calcium | 25 | $327 |
| Losartan Potassium | 36 | $241 |
| Lisinopril | 19 | $238 |
| Amlodipine Besylate | 36 | $198 |
| Escitalopram Oxalate | 11 | $170 |
| Methocarbamol | 11 | $147 |
| Fluoxetine Hcl | 14 | $134 |
| Quetiapine Fumarate | 13 | $132 |
| Metoprolol Tartrate | 18 | $127 |
| Sertraline Hcl | 13 | $120 |
| Rosuvastatin Calcium | 16 | $108 |
| Gabapentin | 18 | $77 |
| Alprazolam | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other family in New Orleans
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Robert ByramNew Orleans$49K
- Amy SchmittNew Orleans$48K
- Eric BabineauxNew Orleans$32K
- Cherie AlbroNew Orleans$29K
- Aimee ScroggsNew Orleans$20K
- Kelly BaquetNew Orleans$18K
- Lori LemoineNew Orleans$17K
- Jennifer GreenheckNew Orleans$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.